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The purpose of the study was to analyze and systematize the literature data on the benefit/risk ratio of sofosbuvir administration in the treatment 
of patients with chronic hepatitis C and the main trends in its patent protection. 
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infection. Its indisputable advantages are that this drug can be used with different genotypes of the virus, decompensated liver function, it is well 
tolerated. Sofosbuvir has an improved safety profile and a low probability of viral resistance. The high cost of sofosbuvir is due to the powerful 
patent protection. As mechanisms for working with patent barriers, it is recommended to use the flexible mechanisms of the TRIPS Agreement: the 
grant of compulsory licenses, the implementation of parallel imports, the tightening of the criteria for patentability (prohibition of patenting new 
forms that do not improve therapeutic efficacy). 
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According to World Health Organization, morbidity and mortality 
associated with hepatitis C virus (HCV) infection continue to 
increase worldwide. Each year about 700,000 people die from HCV-
related complications, including liver cirrhosis and hepatocellular 
carcinoma [1-6]. For Ukraine, the problem of HCV infection is really 
not only medically, but also socio-economically important. In 
Ukraine, infection with the hepatitis C virus of people over the age of 
15 reaches 9% and up to 11,000 people die from its effects every 
year [7, 8]. According to the results of selective monitoring of risk 
groups, the level of HCV infection among some of them is much 
higher than the world average rates and reaches 40–60%. It should 
be noted that thanks to scientific breakthroughs towards the 
treatment of HCV infection, significant progress has been made in 
the treatment of this pathology and in fact, chronic hepatitis C has 
been transferred to the category of fully curable diseases. 
Until recently, in Ukraine, the combination of pegylated interferon 
with ribavirin during 48-56 w was considered to be the recognized 
standard of therapy for this pathology. The effectiveness of this 
treatment was approximately 50%, that is, only half of the patients 
undergoing therapy had a chance of cure. But, in almost all cases this 
therapy was a peculiar kind of trial because of side effects, namely 
the “flu-like syndrome”, which accompanied the patient during the 
entire course of therapy [7]. 
Taking into account international recommendations, as well as 
proven high efficacy and favorable safety profile of direct-acting 
antiviral agents (DAAs) in the treatment of chronic HCV, the Unified 
clinical protocol on primary, secondary, tertiary care “Viral hepatitis 
C in adults” was updated by Order of the Ministry of Health of 
Ukraine dated July 18, 2016 No. 729. The HCV treatment regimens of 
all genotypes were revised in the updated document. 
There is no doubt that effective antiviral therapy leading to the 
eradication of HCV infection reduces the risk of progression of hepatic 
and extrahepatic HCV infection manifestations, especially if the 
treatment is carried out before the formation of liver cirrhosis [9-17]. 
At least 6 genotypes and dozens of subgenotypes of HCV, the 
distribution of which differs in different countries of the world, are 
currently described. In Russia, the United States, Europe and some 
other countries, the most common virus is genotype 1 (HCV-1), while 
HCV-3 is the second most common (22-30% of patients) [18-20]. 
As a result, interferon-free regimens with the use of DAAs were 
included in the treatment regimens of patients infected with HCV: 
sofosbuvir+ribavirin; sofosbuvir/ledipasvir; sofosbuvir+simeprevir; 
ombitasvir/paritaprevir/ritonavir and dasabuvir [21]. 
MATERIALS AND METHODS 
The purpose of the study was to analyze and systematize the 
literature data on the benefit/risk ratio of sofosbuvir administration 
in the treatment of patients with chronic hepatitis C and the main 
trends in its patent protection. 
Studies were conducted using databases on the Internet: Ukrainian 
patent office, the European patent office, the US patent office, the 
Food and drug administration, European Medicines Agency (EMEA), 
State enterprise “The State Expert Center” of the Ministry of Health 
of Ukraine. It has used retrospective, logical, systematic and 
analytical methods. 
RESULTS AND DISCUSSION 
The recommendations of the World Health Organization [22], the 
European Association for the Study of the Liver (EASL) [23] and the 
American Association for the Study of Liver Diseases (AASLD/The 
Infectious Diseases Society of America (IDSA), which consider 
current approaches to the treatment of chronic hepatitis C were 
published. All these recommendations proposed to use regimens 
that include sofosbuvir as one of the main regimens of antiviral 
therapy for chronic hepatitis [24]. 
Sofosbuvir is a nucleotide pan-genotypic inhibitor of the main 
replicative enzyme, the RNA-dependent RNA polymerase of the 
NS5B region of HCV. Sofosbuvir is a prodrug that, during 
intracellular metabolism, is transformed into a pharmacologically 
active analogue of uridine triphosphate. The standard dose of 
sofosbuvir is one 400 mg pill, which is taken as a single piece after a 
meal. After administration, sofosbuvir is rapidly absorbed. 
Sofosbuvir (mainly in the form of an inactive metabolite leaving 
hepatocytes after dephosphorylation) is characterized by an active 
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secretion of the renal tubules (80%). Sofosbuvir can be prescribed in 
a full dose only for mild and moderate renal impairment, while its 
use is not recommended in patients with severe renal insufficiency 
(glomerular filtration rate<30 ml/min/1.73 m2) and in patients 
receiving treatment hemodialysis [25-27]. 
Although in case of moderate and severe hepatic insufficiency, the 
area under the concentration curve of sofosbuvir increases by 126% 
and 143%, and the active metabolite increases by 18% and 9%, 
respectively, nevertheless, sofosbuvir can be administered in full 
dose for any degree of hepatic failure. 
Sofosbuvir has activity against all known HCV genotypes, has a high 
resistance barrier and the favorable safety profile [28]. Most adverse 
events observed in the clinical trials of sofosbuvir are associated 
with the simultaneous use of pegylated interferon and (or) ribavirin. 
The efficacy and safety of sofosbuvir in patients with different HCV 
genotypes and various combinations of drugs were studied in large, 
well-designed clinical studies of the II and III phase (NEUTRINO 
[29], PROTON [30], ELECTRON [31], ATOMIC [32], COSMOS [33], 
FUSION [34], FISSION [29], NUCLEAR [35], POSITRON [34]) and 
systematized by Harmeet KB 
 
et al. [36]. In clinical studies of the II 
phase, it was found that the most effective dose of sofosbuvir is 400 
mg with the duration of treatment from 12 to 24 w in various 
combinations with pegylated interferon and ribavirin. Similar 
results were obtained in numerous clinical studies of the III phase. 
Research results indicate a good safety profile of sofosbuvir. In its 
application, there was only a slight decrease in hemoglobin level and 
a much lower overall incidence of side effects compared with 
pegylated interferon-based regimens. The most frequently reported 
side effects were a headache, insomnia, general weakness, nausea, 
dizziness, pruritus, upper respiratory tract infections, skin rash, back 
pain, anemia grade 1, lymphopenia grade 4. While taking sofosbuvir, 
no cases of neutropenia, thrombocytopenia, or other serious side 
effects have been reported. In the groups of patients who received 
monotherapy, the only side effects that were likely to be associated 
with sofosbuvir were nausea and general weakness. Compared to a 
pegylated interferon-based regimen, tolerability of sofosbuvir 
monotherapy was significantly better. The data obtained indicate 
the efficacy and safety of sofosbuvir. 
Table 1: Meta-analysis of the effectiveness and safety of sofosbuvir 
Study Results 
1 2 
Meta-analysis of six trials 
(2346 patients; 1625 
treated with sofosbuvir
It has not established an increased risk of cardiac outcomes, including arrhythmias (and bradycardia), among 
) 
sofosbuvir-treated patients [38]. 
Meta It has showed that the 12-week regimen of -analysis of six 
randomized trials (n=1427 
patients) 
sofosbuvir plus velpatasvir was highly effective in HCV patients, including 
those with cirrhosis and former treatment experience. Except for genotype-3, adding ribavirin was not associated 
with significant improvements in SVR12 rates [39].  
Meta-analysis of 16 trials 
(n=885 patients) 
It has evaluated safety and efficacy of different combinations of direct-acting antivirals (DAAs: Sofosbuvir
Meta-analysis of 15 studies 
(4230 patients) 
/ledipasvir 
(SOF/lDV), Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir (PrOD), Daclatasvir (DCV)/Simeprevir (SMV)±Ribavirin 
(RBV) and SOF/SMV±RBV, Asunaprevir/Daclatavir (ASV/DCV)) in 885 liver transplant recipients with genotype 1 
HCV) has carried out. It has established that DAA treatment is highly effective and well tolerated in liver transplant 
recipients with recurrent genotype 1 HCV infection [40].  
It has established that sofosbuvir+ribavirin for 24 w is the most widely used and generally well-tolerated DAA 
therapy in Asia. However, its effectiveness is not optimal in chronic hepatitis C (Genotype 3) patients with cirrhosis 
[41].  
Meta-analysis of 7 studies 
(n = 1167 co-infected 
patients) 
It has evaluated 
Meta-analysis of 41 studies 
(n = 8574 patients) 
efficacy and safety of sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C 
virus and human immunodeficiency virus. The results of this study showed that the treatment response of 
sofosbuvir-containing regimens in patients co-infected with HIV and HCV was satisfied. Attention should be paid to 
the high rates of adverse events [42]. 
All oral direct-acting antiviral (daclatasvir/asunaprevir, ledipasvir/sofosbuvir±ribavirin) regimens treatment of HCV 
GT1 resulted in high cure rates in Asian patients in routine clinical practice setting including elderly patients and 
those with end-stage renal disease [43].  
Review of data of 3311 
patients 
It has established that the optimal therapeutic regimen for patients with HCV genotype 3 appears to be the 
combination sofosbuvir/daclatasvir, administered for 12 w without the use of RBV in non-cirrhotic patients. In 
cirrhotics the meta
8 studies (n =1892 
patients) 
-analytic approach suggests extending therapy to 24 w [44].  
 
The combination of sofosbuvir
7 studies (n = 379 
patients) 
 and ledipasvir achieved high sustained virological response rates (>90%) in both 
cirrhotic and non-cirrhotic patients with HCV genotype-1. The addition of ribavirin to this regimen did not 
significantly increase the sustained virological response rates [45]. 
Sofosbuvir+daclatasvir
10 studies (n =2248 
patients) 
±ribavirin, regimen is of high efficacy and tolerability in liver transplant recipients with HCV 
infection [46]. 
The interferon-free regimen of sofosbuvir/ledipasvir for 12 or 24 w with or without ribavirin is highly effective for 
treatment of patient’s withHCV genotype 1 infection [47]. 
 
1 2 
7 studies (n =2626 
patients) 
 
Ledipasvir-sofosbuvir based therapy is a safe and effective treatment for patients with genotype 1 HCV. The addition of 
ribavirin to ledipasvir-sofosbuvir may increase toxicity without achieving improved efficacy. Large-scale and high-quality 
clinical research is still needed to confirm the results [48]. 
12 studies (n =994 
patients) 
Ledipasvir+sofosbuvir
7 studies (n =2601 
patients) 
-based treatment is highly effective and well tolerated in liver transplant recipients with HCV 
reinfection [49]. 
 
The 12-week or 24-week sofosbuvir+ledipasvir regimen with a low incidence of adverse events is as effective and well 
tolerated as the sofosbuvir+
9 studies (n =325 
patients)  
ledipasvir+ribavirin regimen for the treatment of patients with chronic HCV genotype 1 
infection [50]. 
Simeprevir+sofosbuvir
27 studies (n =3415 
patients) 
±ribavirin is safe and effective in recipients with liver transplant with HCV-1 infection [51]. 
Regimens containing sofosbuvir
18 studies (n =2975 
patients) 
 and velpatasvir to be the best option for patients with HCV genotype 3 infections. 
Analyses indicated that ribavirin significantly increases SVR rates and should be considered if tolerated [52]. 
The sofosbuvir-containing regimens in patients with HCV genotype 2 infection have better efficacy than in patients with 
HCV genotype 3 infections [53]. 
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For further conducting pharmacokinetics studies and therapeutic 
drug monitoring it has developed a simple, accurate, precise, linear, 
rugged and rapid RP-HPLC method for quantitative estimation of 
sofosbuvir in human plasma [37]. 
Although numerous placebo-controlled studies of sofosbuvir are 
important evidence of its efficacy, there is a higher degree of evidence 
of its clinical benefits. The recognized standard of evidence-based 
medicine is a meta-analysis of the results of numerous studies. These 
sofosbuvir meta-analysis data are given in table 1. 
 
Thus, the existing evidence base suggests that the use of sofosbuvir is 
effective and safe in patients in course of the treatment of viral hepatitis 
C, although the risk of side effects, such as fatigue, headache and nausea, 
cannot be totally excluded. Their severity increases with combination 
therapy with interferon and other antiviral drugs [54, 55]. 
Table 2: Analysis of patent protection of sofosbuvir and its combinations in the USA 
Active pharmaceutical ingredient, trademark; Patent No dosage form Patent Expiration 
2 1 3 
sofosbuvir;  
SOVALDI;  











ledipasvir, sofosbuvir;  
HARVONI;  
Tablet oral, 


















sofosbuvir, velpatasvir;  
EPCLUSA;  
Tablet; oral, 
















1 2 3 
sofosbuvir, velpatasvir, voxilaprevir;  
VOSEVI;  
Tablet; oral, 
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It should be noted that sofosbuvir not only potentially provides a 
cure but challenges health care systems [56-63]. 
Access to innovative drugs and diagnostics is an important 
element in the control and treatment of hepatitis C infection. The 
prices requested for the new hepatitis C drugs, in particular, the 
direct-acting antivirals as sofosbuvir, are unsustainable for most 
countries’ health budgets. These prices may deprive thousands of 
patients of a curative treatment. Consequently, it remains 
accessible only to the most severely ill patients, in many countries 
these patients are with hepatic fibrosis F3A4, and early stages are 
not treated. Hence, this transmissible disease will continue to 
drive new infections. 
As of 2016, a 12-week course of sofosbuvir treatment costs about 
US$84,000 in the United States, US$53,000 in the United Kingdom, 
US$45,000 in Canada, and about US$500 in India [64-66]. 
On 15 September 2014 Gilead Sciences INC signed licensing 
agreements with seven Indian generic manufacturers (Cadila, Cipla, 
Hetero, Mylan, Ranbaxy, Sequent and Strides Arcolab), allowing 
these companies to manufacture sofosbuvir in India and sell it in 
The high cost of sofobusfir is related to its patent protection. The 
analysis of sofobusfir patenting revealed its powerful patent 
protection (table 2). The substance is protected by several patents in 
many countries. The expiration of a number of patents for sofosbuvir 
falls on the years of 2028-2034. This allows the pharmaceutical 
company, Gilead Sciences INC, to have a monopoly for the sale over a 
long period and improve their commercial prospects. 
91
In March, 2017 the Patent EP 2604620 (Modified fluorinated 
nucleoside analogues) was challenged by “European Public Health 
Alliance”, “Doctors Without Borders”, “Doctors of the World” and 
several more international organizations [67].  
 
low-and-middle-income countries. Generic companies pay 7% 
royalties and are free to set their own prices but have to produce or 
buy the active pharmaceutical ingredient in India. One company was 
quoted with an entry price of around US$ 300. One 
nongovernmental organization expects entry prices of US$ 400 per 
12-week course and in the medium term a reduction to around US$ 
135. Nevertheless, these generic products–which may become 
available within 12–18 mo–can only be used in the 91 countries 
listed, and the agreement only covers four countries in Europe: 
Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan. Countries that 
are not included can negotiate price or issue compulsory licenses to 
access the Indian generic versions [64]. 
On 13 September 2018 the European Patent Office (EPO) ruled in 
favour of the pharmaceutical company Gilead and maintained the 
company’s patent on hepatitis C drug sofosbuvir. The patent, 
however, is maintained in an amended form. Civil society involved in 
the case expressed dismay over the outcome and its potential effect 
on European drug prices. 
According to report of the world community advisory board on HCV 
generics and diagnostics other sofosbuvir patent oppositions in the 
world are given in table 3 [68].  
Analysis of the range of sofosbuvir and management of the 
intellectual property in Ukraine is given in the table 4. 
The problem of viral hepatitis is common to many countries of the 
world, and Ukraine is no exception. For the combined interferon-
free regimens recommended for the treatment of patients with 
different HCV genotypes and at the same time available in Ukraine 
are sofosbuvir+ledipasvir; paritaprevir+ombitasvir+dasabuvir+ 
ritonavir; ombitasvir+paritprevir+ritonavir, sofosbuvir+simeprevir. 
 
At the same time, the recommendations of EASL 2016 allow for the 
use of a combination of ledipasvir+sofosbuvir in patients with HCV 
1st genotype (any subtype) without cirrhosis and past treatment 
experience in the abbreviated regime–for an 8-week course. In 2016, 
when sofosbuvir was added to the treatment regimen, the frequency 
of achieving a sustained virological response 12 w after the end of 
therapy (at least 95% of cases) was 95.2%. 
Table 3: Sofosbuvir patent oppositions (
Patent opposed 
according to report of the world community advisory board on HCV generics and diagnostics 
[68]) 
Patent international 




(civil society only) 







Argentina FGEP 2015 Under examination 
China I-MAK 2015 Patent rejected in 2015, 
appeal pending 
Europe MDM 2015 Maintained in an amended 
form; under appeal 
India DNP+, I-MAK 2013 Under examination 
Russia ITPCru 2015 Partially revoked (Appeal) 





“Modified fluorinated nucleoside 
analogues” 
 
Argentina FGEP 2017 Opposition filed 
Brazil ABIA 2015 Opposition filed, preliminary 




2017 Invalidation filed, case pending 
Europe MDM 2017 Under examination 
Europe MSF 2017 Under examination 
Europe Consortium of six 
European NGOs 
2017 Under examination 
India DNP+, I-MAK 
 
2013 Refused first but granted later. In 





India DNP+, I-MAK 2017 Under examination 




“Methods for the preparation of 
diastereomerically pure 
phosphoramidate prodrugs” 





“Methods for treating HCV” 
Ukraine AUN of PLWH 2016 Under examination 
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Sofosbuvir registration and management of intellectual property in Ukraine 
Trademark Active pharmaceutical 
ingredients 






sofosbuvir, 400 mg, film-
coated tablets 
Drug is manufactured under 
license from Gilead Science 
Ireland UC 
no data available 
09.10.2015-
09.10.2020 




Patent of Ukraine № 110354 15550 
Patent of Ukraine № 115664 
20.11.2018 
20.11.2025 
Virpas ledipasvir, 90 mg, sofosbuvir, 
400 mg, film-coated tablets 
Strides Shasun Ltd, 
India 
Drug is manufactured under 
license from Gilead Science 
no data available 
07.11.2018- Sofgen 
07.11.2023 
Hetero Labs Limited., 
India 
sofosbuvir, 400 mg, film-
coated tablets 
Drug is manufactured under 





Virso Strides Shasun Ltd, 
India 
sofosbuvir, 400 mg, film-
coated tablets 
Drug is manufactured under 
license from Gilead Science 
no data available 
07.11.2018- Sofgen-L 
07.11.2023 
ledipasvir, 90 mg, sofosbuvir, 
400 mg, film-coated tablets 
Hetero Labs Limited., 
India 
Drug is manufactured under 




Harvoni Gilead Sciences, 
Ireland UC 
ledipasvir, 90 mg, sofosbuvir, 
400 mg, film-coated tablets 
Patent of Ukraine № 110354 




Epclusa velpatasvir, 100 mg, sofosbuir, Gilead Sciences, 
Ireland UC. 400 mg, film-coated tablets 
Patent of Ukraine № 110354 
Patent of Ukraine № 115664 
no data available 
 
*-according to https://www. apteka. ua/drugsearch?lang=en 
Clinical studies carried out in Ukraine have shown that the 
advantages of the second generation DAAs drugs are the possibility 
of oral treatment with a reduction in the number of times the drug is 
taken, a decrease in the duration of HCV treatment (up to 8-24 w) 
with an improvement in the safety profile and an increase in the 
effectiveness of therapy 90% [7,69,70]. The economic component, as 
well as social and political support are critical factors determining 
the possibility of elimination in terms of identifying the disease, its 
diagnosis and strategies to combat it. 
In order to increase the availability of sofosbuvir for patients with 
hepatitis C is necessary the use of the “flexible” mechanisms of the 
TRIPS Agreement (Agreement on trade-related aspects of 
intellectual property rights), namely involving the grant of 
compulsory licenses, the implementation of parallel imports, the 
tightening of the criteria for patentability etc. [71-80]. 
CONCLUSION 
Data from clinical studies abroad and meta-analyses indicate that 
sofosbuvir is one of the most promising drugs for the treatment of 
chronic HCV infection. Its indisputable advantages are that this drug can 
be used with different genotypes of the virus, decompensated liver 
function, it is well tolerated. Sofosbuvir has an improved safety profile 
and a low probability of viral resistance. The drug is recommended by 
the World Health Organization, the European Association for the Study 
of the Liver (EASL) and the American Association for the Study of Liver 
Diseases (AASLD/the Infectious Diseases Society of America (IDSA), and 
also entered the Unified clinical protocol on primary, secondary, tertiary 
care “Viral hepatitis C in adults” of Ukraine (2016). 
The high cost of sofosbuvir is due to the powerful patent protection. 
As mechanisms for working with patent barriers, it is recommended 
to use the flexible mechanisms of the TRIPS Agreement: the grant of 
compulsory licenses, the implementation of parallel imports, the 
tightening of the criteria for patentability (prohibition of patenting 
new forms that do not improve therapeutic efficacy
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